All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.
Given the promising results using CARs in targeting hematological malignancies, efforts have been made to use CARs to redirect T cells for other purposes. Adoptive transfer of regulatory T cells (Tregs) for the treatment of various diseases is an active area of research. In contrast to cytotoxic T cells, Tregs can suppress lymphocytes against other antigens in the local microenvironment (often referred to as "bystander suppression") without destroying normal cells expressing the target antigen. Several groups have explored the use of CARs to target Tregs to specific immune cell populations in preclinical models of graft-versus-host disease, organ transplantation, and various autoimmune diseases.
Our CAR-Treg cells were designed by incorporating a second-generation CAR into PBMC-derived Treg cells using lentiviral transduction technology. These CAR-Treg cells are expected to lyse tumor cells in vitro and exhibit antitumor functions in vivo.
There are currently no customer reviews or questions for Anti-CD37 (XP5-2333) h(4-1BB-CD3ζ) CAR-Treg Cells (XS-0622-ZP2333). Click the button below to contact us or submit your feedback about this product.
For research use only. Not intended for any clinical use. No products from Creative Biolabs may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative Biolabs.
For any technical issues or product/service related questions, please leave your information below. Our team will contact you soon.
The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders
LEARN MORE NEWSLETTERCellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.
LEARN MORE SOLUTIONSilence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.
LEARN MORE NOVEL TECHNOLOGYCanine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.
LEARN MORE SOLUTION